Skip to main
SBRA
SBRA logo

SBRA Stock Forecast & Price Target

SBRA Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 30%
Buy 26%
Hold 39%
Sell 4%
Strong Sell 0%

Bulls say

Sabra Health Care REIT Inc has demonstrated an improvement in its financial metrics, with the net debt to adjusted EBITDA ratio decreasing to 5.3x from 5.7x over the past year, reflecting enhanced operational efficiency. The company has also reported a 4Q24 Core FFO of $0.35 per share, aligning with consensus expectations, and subsequently raised its Core FFO estimates for FY2025 and FY2026, indicating positive momentum in earnings. Additionally, Sabra's strong liquidity position of $953.9 million and robust performance in its skilled nursing and SHOP assets positions the company favorably for growth in a competitive industry.

Bears say

Sabra Health Care REIT faces substantial financial challenges due to a heightened debt level, which may hinder its ability to meet financial obligations and sustain business operations. The reliance on government reimbursements and the potential for loss of licenses pose significant risks to revenue generation, especially considering potential regulatory compliance issues and reimbursement rate reductions. Furthermore, difficulties in accessing external capital for future investments may limit growth opportunities and delay recovery on investments, while competitive pressures exacerbate operational uncertainties.

SBRA has been analyzed by 23 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 26% recommend Buy, 39% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sabra Health Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sabra Health Care (SBRA) Forecast

Analysts have given SBRA a Buy based on their latest research and market trends.

According to 23 analysts, SBRA has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sabra Health Care (SBRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.